Information de reference pour ce titreAccession Number: | 00007783-201004000-00005.
|
Author: | Ratjen, Felix 1; Munck, Anne 2; Kho, Pearl 3; Angyalosi, Gerhild 4; for the ELITE Study Group *
|
Institution: | (1)Hospital for Sick Children, Toronto, Canada (2)Hospital Robert Debre, AP-HP Paris, France (3)Novartis Horsham Research Centre, Horsham, West Sussex, UK (4)Novartis Pharma AG, Basel, Switzerland
|
Title: | |
Source: | Thorax. 65(4):286-291, April 2010.
|
Abstract: | Rationale: Antibiotic therapy for early Pseudomonas aeruginosa infection in patients with cystic fibrosis (CF) is effective, but the optimal therapeutic regimen and duration for early treatment remains unclear. The EarLy Inhaled Tobramycin for Eradication (ELITE) study was designed to assess the efficacy and safety of two regimens (28 and 56 days) of tobramycin inhalation solution (TIS) 300 mg/5 ml twice daily for the treatment of early onset P aeruginosa infection in patients with CF.
Methods: In this open-label randomised multicentre study, patients with CF (aged >=6 months) with early P aeruginosa infection were treated for 28 days with TIS twice daily administered by the PARI LC PLUS (PARI GmbH, Starnberg, Germany) jet nebuliser. After 28 days, patients were randomised 1:1 to either stop TIS (n=45) or to receive a further 28 days of TIS (n=43). The primary endpoint was the median time to recurrence of P aeruginosa (any strain). Secondary endpoints included the proportion of patients free of P aeruginosa infection 1 month after cessation of therapy and safety assessments.
Results: The median time to recurrence of P aeruginosa (any strain) was similar between the two groups. In total, 93% and 92% of the patients were free of P aeruginosa infection 1 month after the end of treatment and 66% and 69% remained free at the final visit in the 28-day and 56-day groups, respectively. TIS was well tolerated.
Conclusions: Treatment with TIS for 28 days is an effective and well tolerated therapy for early P aeruginosa infection in patients with CF.
Trial registration number: NCT00391976.
(C) 2010 BMJ Publishing Group Ltd & British Thoracic Society
|
Author Keywords: | Cystic fibrosis; tobramycin; Pseudomonas aeruginosa.
|
References: | 1. Emerson J, Rosenfeld M, McNamara S, et al.. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100.
2. Kosorok MR, Zeng L, West SE, et al.. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001;32:277-87.
3. Littlewood JM, Miller MG, Ghoneim AT, et al.. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Lancet 1985;13:865.
4. Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991;338:725-6.
5. Wiesemann HG, Steinkamp G, Ratjen F, et al.. Placebo-controlled, double-blind, randomized study of aerolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998;25:88-92.
6. Ratjen F, Doring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001;358:983-4.
7. Doring G, Conway SP, Heijerman HGM, et al.. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000;16:749-67.
8. Doring G, Hoiby N. Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004;3:67-91.
9. Touw DJ, Brimicombe RW, Hodson ME, et al.. Inhalation of antibiotics in cystic fibrosis. Eur Respir J 1995;8:1594-604.
10. Rosenfeld M, Cohen M, Ramsey B. Aerosolized antibiotics for bacterial lower airway infections: principles, efficacy and pitfalls. Clin Pulm Med 1997;4:101-12.
11. Gibson RL, Emerson J, McNamara S, et al.. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003;167:841-9.
12. Gibson RL, Emerson J, Mayer-Hamblett N, et al.. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 2007;42:610-23.
13. Doring G, Obernesser JH, Botzenhart K. Extracellular toxins of Pseudomonas aeruginosa. III. Radioimmunoassay for detection of alkaline protease. Zentralbl Bakteriol Mikrobiol Hyg A 1982;252:239-47.
14. Munck A, Bonascorsi S, Mariani-Kurkdijian P, et al.. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr Pulmonol 2001;32:288-92.
15. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23:330-5.
16. Lee TW, Brownlee KG, Denton M, et al.. Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center. Pediatr Pulmonol 2004;37:104-10.
17. Taccetti G, Campana S, Festini F, et al.. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005;26:458-61.
18. Hansen CR, Pressler T, Hoiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 2008;7:523-30.
19. National Heart, Lung and Blood Institute, Cystic Fibrosis Foundation, CF Therapeutics Development Network Coordinating Center. Comparison of two treatment regimens to reduce PA infection in children with cystic fibrosis (EPIC). Bethesda, Maryland: National Library of Medicine (US), 2004. http://clinicaltrials.gov/ct2/sh...- ouverture dans une nouvelle fenêtre (accessed Jan 2009).
20. Ratjen F. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr Opin Pulm Med 2006;12:428-32.
21. Kozlowska WJ, Bush A, Wade A, et al.. Lung function from infancy to the preschool years after clinical diagnosis of cystic fibrosis. Am J Respir Crit Care Med 2008;178:42-9.
22. Kumana CR, Yuen KY. Parenteral aminoglycoside therapy. Selection, administration and monitoring. Drugs 1994;47:902-13.
|
Language: | English.
|
Document Type: | Cystic fibrosis.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0040-6376
|
NLM Journal Code: | vqw, 0417353
|
DOI Number: | https://dx.doi.org/10.1136/thx.2...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|